Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655310 | 0.90 | MGLL (0.30) | — | |
| SCHEMBL5655348 | 0.89 | BID (0.31) | NAAAMEN1ALDH1A1MAPTHTT | |
| SCHEMBL30240774 | 0.89 | BID (0.31) | NAAAMEN1ALDH1A1MAPTHTT | |
| SCHEMBL5656636 | 0.89 | PTGS1 (0.30) | — | |
| SCHEMBL1276666 | 0.87 | MEN1 (0.35) | NAAAMEN1ALDH1A1MAPTHTT | |
| Dymanthine SCHEMBL1276492 | 0.87 | DNM1 (0.40) | NAAAMEN1ALDH1A1MAPTHTT | |
| SCHEMBL5656345 | 0.87 | MEN1 (0.33) | NAAAMEN1ALDH1A1MAPTHTT | |
| SCHEMBL5653811 | 0.87 | MEN1 (0.33) | NAAAMEN1ALDH1A1MAPTHTT | |
| SCHEMBL5872296 | 0.87 | MEN1 (0.33) | NAAAMEN1ALDH1A1MAPTHTT | |
| SCHEMBL29661112 | 0.83 | MEN1 (0.33) | NAAAMEN1ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872844-B2 | Metal complexes containing acetylenic ligands, polymerization catalysts and addition polymerization process | THE DOW CHEMICAL COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-6825147-B2 | (3,4-DIPHENYLCYCLOPENTADIEN-1-YL)DIMETHYL(T-BUTYLAMIDO) -SILANETITANIUM DICHLORIDE, FOR EXAMPLE; FOR COPOLYMERIZATION OF ETHYLENE AND STYRENE | DOW GLOBAL TECHNOLOGIES INC. | 2004-11-30 | — | — | US | disclosed |
| US-20020183464-A1 | 3-aryl-substituted cyclopentadienyl metal complexes and polymerization process | DOW GLOBAL TECHNOLOGIES LLC | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183464-A1 | 3-aryl-substituted cyclopentadienyl metal complexes and polymerization process | SOD1, AOC3, PPOX | NAAA 4415/4885MEN1 4838/4885ALDH1A1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.